Workflow
CT/MR/MI/XR/RT产品线设备
icon
Search documents
联影医疗(688271):25Q3收入增速亮眼,海外占比持续提升
Guoxin Securities· 2025-11-05 11:14
Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Insights - The company reported significant revenue growth in Q3 2025, with a year-on-year increase of 75.41%, leading to a turnaround in profitability [1] - The domestic market is steadily recovering, while the overseas market shows impressive growth, with a 42.0% increase in revenue [2] - The gross margin slightly decreased to 47.02%, primarily due to price competition from centralized procurement [2] - The company maintains its profit forecast, expecting revenue growth of 20.4% in 2025, with net profit projected to increase by 54.5% [2] Summary by Sections Financial Performance - In the first three quarters of 2025, the company achieved revenue of 88.59 billion yuan, up 27.39%, and a net profit of 11.20 billion yuan, up 66.91% [1] - Q3 2025 alone saw revenue of 28.43 billion yuan and a net profit of 1.22 billion yuan, marking increases of 75.41% and 143.80%, respectively [1] - Revenue from equipment sales reached 70.71 billion yuan, with various product lines showing growth rates between 8% and 40% [1] Market Dynamics - Domestic revenue for the first three quarters of 2025 was 68.66 billion yuan, reflecting a 23.7% increase, driven by accelerated equipment updates and a recovering bidding market [2] - The overseas market contributed 19.93 billion yuan, with a revenue share of 22.5%, indicating a strong growth trajectory [2] Cost Management - The company reported a slight decline in gross margin to 47.02%, attributed to price competition [2] - Significant reductions in expense ratios were noted, with sales, management, and R&D expense ratios all decreasing [2] Future Projections - Revenue forecasts for 2025-2027 are set at 124.1 billion yuan, 145.1 billion yuan, and 169.4 billion yuan, with corresponding net profits of 19.5 billion yuan, 23.7 billion yuan, and 27.7 billion yuan [2] - The current stock price corresponds to a PE ratio of 58, 48, and 41 for the years 2025, 2026, and 2027, respectively [2]